Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
LAVA Therapeutics N.V. - Ordinary Shares
(NQ:
LVTX
)
1.495
-0.015 (-0.99%)
Streaming Delayed Price
Updated: 2:00 PM EDT, Oct 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
601,001
Open
1.520
Bid (Size)
1.490 (121)
Ask (Size)
1.500 (22)
Prev. Close
1.510
Today's Range
1.470 - 1.530
52wk Range
0.8502 - 2.093
Shares Outstanding
26,289,087
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Thursday's after hours session: top gainers and losers
October 02, 2025
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
October 02, 2025
From
XOMA Royalty Corporation; LAVA Therapeutics
Via
GlobeNewswire
Performance
YTD
+45.1%
+45.1%
1 Month
-2.9%
-2.9%
3 Month
+6.0%
+6.0%
6 Month
+21.5%
+21.5%
1 Year
-6.6%
-6.6%
More News
Read More
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting
September 30, 2025
Via
Stocktwits
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week
September 03, 2025
Via
Benzinga
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
August 05, 2025
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
August 04, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
August 04, 2025
From
Halper Sadeh LLC
Via
Business Wire
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
August 04, 2025
From
XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via
GlobeNewswire
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
February 28, 2025
Via
Benzinga
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
February 27, 2025
Via
Benzinga
On Wednesday, there are stocks with unusual volume. Let's take a look.
February 26, 2025
Via
Chartmill
What's going on in today's session
February 25, 2025
Via
Chartmill
Which stocks are experiencing notable movement on Tuesday?
February 25, 2025
Via
Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session.
February 25, 2025
Via
Chartmill
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
August 20, 2024
Via
InvestorPlace
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 20, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Announces Annual Meeting of Shareholders
June 10, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 21, 2024
Via
InvestorPlace
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
May 21, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
May 06, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 20, 2024
Via
InvestorPlace
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
March 20, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024
Via
FinancialNewsMedia
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Frequently Asked Questions
Is LAVA Therapeutics N.V. - Ordinary Shares publicly traded?
Yes, LAVA Therapeutics N.V. - Ordinary Shares is publicly traded.
What exchange does LAVA Therapeutics N.V. - Ordinary Shares trade on?
LAVA Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares?
The ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares is LVTX on the Nasdaq Stock Market
What is the current price of LAVA Therapeutics N.V. - Ordinary Shares?
The current price of LAVA Therapeutics N.V. - Ordinary Shares is 1.495
When was LAVA Therapeutics N.V. - Ordinary Shares last traded?
The last trade of LAVA Therapeutics N.V. - Ordinary Shares was at 10/16/25 02:00 PM ET
What is the market capitalization of LAVA Therapeutics N.V. - Ordinary Shares?
The market capitalization of LAVA Therapeutics N.V. - Ordinary Shares is 39.30M
How many shares of LAVA Therapeutics N.V. - Ordinary Shares are outstanding?
LAVA Therapeutics N.V. - Ordinary Shares has 39M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.